Efficacy and Safety of Intracameral Moxoft Eye Drops (Moxifloxacin Ophthalmic Solution 0.5%) for Endophthalmitis Prophylaxis in Cataract Surgery.
Loading...
Date
2013-04
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Objective: To evaluate the efficacy and safety of
intracameral Moxoft eye drops (Moxifloxacin ophthalmic
solution 0.5%) administered at the conclusion of
phacoemulsification cataract surgery for the purpose of
endophthalmitis prophylaxis. Design: Open label, multicentre,
prospective. Setting: Three ophthalmologists across
India. Methods: A total of 134 outpatients of either sex
undergoing phacoemulsification with no ocular pathology
other than cataract and meeting all inclusion/exclusion
criteria were enrolled in the study. All patients received preoperatively
1 drop of Moxoft eye drops (Moxifloxacin
ophthalmic solution 0.5%) topically every 15 minutes atleast
4 times one hour prior to surgery. 0.1 ml moxifloxacin
solution was aspirated into the tuberculin syringe and
injected into the capsular bag under the capsulorhexis edge
after completion of the Phacoemulsification and IOL
implantation. Post-operative treatment was as per standard
protocol. Patients were assessed pre-operatively and on
day 1, day 7 & day 30 after surgery for ocular symptom
scores for pain in eyes, ocular discharge, hazy cornea,
conjunctival hyperemia, and hypopyon and chemosis.
Anterior chamber (AC) reaction was graded (if present)
on all the visits with fixed slit-lamp settings and on 5-point
rating scale for AC flare and cells in AC. Global assessment
was done for efficacy and tolerability at the end of therapy
on a 3-point scale. Result: Thirteen patients were excluded
from the analysis due to insufficient data and an intentionto-
treat analysis was done for efficacy on 121 patients.
There was significant reduction in scores of pain in eyes,
conjunctival hyperemia, mean AC flare, mean AC cells
(p<0.0001 for all) and ocular discharge (p=0.018).
Hypopyon and/or corneal endothelial cell damage was
observed in none of the patients. Therapy was rated good
to excellent on efficacy and tolerability parameters with no
reporting of a poor rating. Conclusion: Moxoft eye drops
(Moxifloxacin ophthalmic solution 0.5%) is safe for use
by intracameral administration with no corneal
decompensation. Tolerability and post-operative results
were found to be excellent.
Description
Keywords
endophthalmitis, moxifloxacin, cataract, intracameral
Citation
Ramanuj Hitesh, Khandke D A, Adya Hitesh, Shewale R V. Efficacy and Safety of Intracameral Moxoft Eye Drops (Moxifloxacin Ophthalmic Solution 0.5%) for Endophthalmitis Prophylaxis in Cataract Surgery. Indian Medical Gazette. 2013 Apr ; 147 (4): 140-146.